ADMA Biologics successfully implements ADMAlytics

ADMA Biologics announced the successful initial use of its Artificial Intelligence program, named ADMAlytics. ADMAlytics combines AI and machine learning to improve and predict outcomes for production and operational processes. Recently, ADMA successfully produced its first batch of ASCENIV utilizing this innovative ADMAlytics software to prospectively automate and realize efficiency improvements to plasma pooling during commercial manufacturing. “We’re proud to announce the successful development and implementation of our innovative ADMAlytics AI program,” said Adam Grossman, President and Chief Executive Officer of ADMA. “This achievement aligns seamlessly with our overarching mission to continuously innovate our production processes for specialty biologics, while also building on our reputation as a thought leader within the commercial specialty biologics markets for the patients our therapies serve.”